Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 16, 1-10

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date


Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date

Xiaoming Jia et al. Vasc Health Risk Manag.


Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.

Keywords: cardiovascular outcome; eicosapentaneoic acid; icosapent ethyl; omega-3 fatty acids.

Conflict of interest statement

Salim Virani report grants from US Department of Veterans Affairs, grants from World Heart Federation, grants from Jooma and Tahir Family, Honorarium for role as the Associate Editor for Innovations from American College of Cardiology, Steering Committee Member (No financial remuneration) from Patient and Provider Assessment of Lipid Management, outside the submitted work. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles


    1. McLennan PL. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids. 2001;36(Suppl):S111–S114. doi:10.1007/s11745-001-0692-x - DOI - PubMed
    1. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107(21):2646–2652. doi:10.1161/01.CIR.0000069566.78305.33 - DOI - PubMed
    1. Kim W, Khan NA, McMurray DN, Prior IA, Wang N, Chapkin RS. Regulatory activity of polyunsaturated fatty acids in T-cell signaling. Prog Lipid Res. 2010;49(3):250–261. doi:10.1016/j.plipres.2010.01.002 - DOI - PMC - PubMed
    1. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–2067. doi:10.1016/j.jacc.2011.06.063 - DOI - PubMed
    1. Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579–585. doi:10.1161/CIRCRESAHA.115.306398 - DOI - PMC - PubMed

MeSH terms